Macroaxis Stories

Our prognosis on NeuroMetrix to bounce back in August

July 23, 2020  By Rifka Kats
Macroaxis Story
As many millenniums are excited about healthcare space, it is only fair to outline NeuroMetrix. We will evaluate why we are still confident in anticipation of a recovery. Is the firm valuation sustainable? Here I will cover a perspective on valuation of NeuroMetrix to give you a better outlook on taking a position in this stock.
Published over a year ago
View all stories for NeuroMetrix | View All Stories

Reviewed by Raphi Shpitalnik

NeuroMetrix currently holds 1.4 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. The entity currently holds 1.4 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. The firm has a current ratio of 1.66, which is within standard range for the sector. We provide investment recommendation to complement the last-minute expert consensus on NeuroMetrix. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of NeuroMetrix using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NeuroMetrix based exclusively on its fundamental and basic technical indicators. By analyzing NeuroMetrix's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of NeuroMetrix's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeuroMetrix. We calculate exposure to NeuroMetrix's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NeuroMetrix's related companies.

NeuroMetrix Investment Alerts

NeuroMetrix investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring NeuroMetrix performance across your portfolios.Please check all investment alerts for NeuroMetrix

NeuroMetrix Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare NeuroMetrix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeuroMetrix competition to find correlations between indicators driving the intrinsic value of NeuroMetrix.

NeuroMetrix Gross Profit

NeuroMetrix Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing NeuroMetrix previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show NeuroMetrix Gross Profit growth over the last 10 years. Please check NeuroMetrix's gross profit and other fundamental indicators for more details.

A Deeper Perspective

NeuroMetrix reported the previous year's revenue of 8.32 M. Net Loss for the year was (6.48 M) with profit before overhead, payroll, taxes, and interest of 4.14 M.
 2017 2018 2019 2020 (projected)
Revenues USD17.09 M16.09 M9.27 M9.88 M
Revenues17.09 M16.09 M9.27 M9.88 M
Revenues USDRevenues

Margins Breakdown

NeuroMetrix profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or NeuroMetrix itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of NeuroMetrix profit margins.
EBITDA Margin(0.425105)
Gross Margin0.33
Profit Margin(0.439132)
NeuroMetrix Earnings before Tax is quite stable at the moment. Also, NeuroMetrix Average Equity is quite stable at the moment.

NeuroMetrix implied volatility may change after the slide

The information ratio is down to -0.14 as of today. NeuroMetrix exhibits very low volatility with skewness of 0.48 and kurtosis of 0.99. However, we advise investors to further study NeuroMetrix technical indicators to make sure all market info is available and is reliable.

The Current Takeaway on NeuroMetrix Investment

Whereas some firms in the medical instruments & supplies industry are either recovering or due for a correction, NeuroMetrix may not be performing as strong as the other in terms of long-term growth potentials. To sum up, as of the 23rd of July 2020, we believe that NeuroMetrix is currently undervalued with very high probability of financial unrest in the next two years. However, our concluding 30 days recommendation on the company is Sell.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of NeuroMetrix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com